These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37328193)

  • 1.
    Chitturi P; Xu S; Ahmed Abdi B; Nguyen J; Carter DE; Sinha S; Arora R; Biernaskie J; Stratton RJ; Leask A
    Ann Rheum Dis; 2023 Sep; 82(9):1191-1204. PubMed ID: 37328193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling.
    Yokoyama Y; Sekiguchi A; Fujiwara C; Uchiyama A; Uehara A; Ogino S; Torii R; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2018 Oct; 70(10):1661-1672. PubMed ID: 29676521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.
    Toyama T; Looney AP; Baker BM; Stawski L; Haines P; Simms R; Szymaniak AD; Varelas X; Trojanowska M
    J Invest Dermatol; 2018 Jan; 138(1):78-88. PubMed ID: 28870693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The yes-associated protein-1 (YAP1) inhibitor celastrol suppresses the ability of transforming growth factor β to activate human gingival fibroblasts.
    Naik A; Chitturi P; Nguyen J; Leask A
    Arch Oral Biol; 2024 Apr; 160():105910. PubMed ID: 38364717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
    Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
    Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis.
    Xie X; Gan H; Tian J; Li F; Chen J; Wang J; Liao J; Li S
    Eur J Clin Invest; 2022 Aug; 52(8):e13791. PubMed ID: 35441708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis.
    Egal ESA; Kamdem SD; Yoshigi M; Yang CC; Pellizzari S; Kameni EM; Helms MN; Assassi S; Henkemeyer M; Frech TM; Mimche PN
    Arthritis Rheumatol; 2024 Aug; 76(8):1303-1316. PubMed ID: 38589317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
    Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis.
    Pashaei M; Farhadi E; Kavosi H; Madreseh E; Enayati S; Mahmoudi M; Amirzargar A
    Inflammopharmacology; 2024 Oct; 32(5):3181-3193. PubMed ID: 39167314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic Sclerosis.
    Zhou X; Trinh-Minh T; Tran-Manh C; Gießl A; Bergmann C; Györfi AH; Schett G; Distler JHW
    Arthritis Rheumatol; 2022 May; 74(5):871-881. PubMed ID: 34807516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.
    Song Y; Zhu L; Li M
    Clinics (Sao Paulo); 2013 Oct; 68(10):1350-7. PubMed ID: 24212843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc).
    Bergmann C; Hallenberger L; Chenguiti Fakhouri S; Merlevede B; Brandt A; Dees C; Zhu H; Zehender A; Zhou X; Schwab A; Chen CW; Györfi AH; Matei AE; Chakraborty D; Trinh-Minh T; Rauber S; Coras R; Bozec A; Kreuter A; Ziemer M; Schett G; Distler JHW
    Ann Rheum Dis; 2021 Aug; 80(8):1048-1056. PubMed ID: 33903093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.